A Phase 3 interventional study of Blinatumomab and Dexamethasone in Leukemia, Acute Lymphoblastic, sponsored by Amgen. Completed at 103 sites in 24 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 23 open to participants now, 39 under way, 11 of them phase 3. blinatumomab · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 24th largest by enrollment, is one of 2 that started in 2015, is one of 11 in phase 3, and was the 10th registered.
2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →23 of the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Australia, France, Israel and 3 more countries
Ages 1–30
The First Affiliated Hospital of Soochow University · Sites in China
Ages 15+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1–18
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Institute of Hematology & Blood Diseases Hospital, China · Sites in China, Hong Kong
Ages 1 mo–18 yrs
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 41 · Phase 3 14 · Phase 4 1
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 40 across 1,952 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 67 across the 61 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 61 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen: 1 open now, 3 under way, 2 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by Amgen, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2015, is one of 5 in phase 3, and was the 13th registered.
Amgen’s Precursor Cell Lymphoblastic Leukemia-Lymphoma studies by the year they started, since 2005.
11 of the studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327894Phase 3Princess Maxima Center for Pediatric OncologyInterfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia | 2027-09 |
| NCT04722848Phase 3Gruppo Italiano Malattie EMatologiche dell'AdultoSequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | 2027-09 |
| NCT06387121Institute of Hematology & Blood Diseases Hospital, ChinaEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL | 2026-12-01 |
| NCT03114865Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsA Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | 2026-12-30 |
| NCT05519579Northside Hospital, Inc.Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia | 2027-02-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 61 studies testing blinatumomab in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
Among Amgen’s 20 in Precursor Cell Lymphoblastic Leukemia-Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
B-precursor ALL is an aggressive malignant disease. Therapy is usually stratified according to risk characteristics to ensure that appropriate treatment is administered to patients with high-risk of relapse. In general, pediatric treatment regimens are more intense than those employed in adults and include courses of combination chemotherapy. Standard of care chemotherapy is associated with considerable toxicity. There is a lack of novel treatment options for subjects who relapse or are refractory to treatment. Therefore, innovative therapeutic approaches are urgently needed. Blinatumomab is a bispecific single-chain antibody construct designed to link B cells and T cells resulting in T cell activation and a cytotoxic T cell response against CD19 expressing cells. This study will evaluate the event-free survival (EFS) after treatment with blinatumomab when compared to standard of care (SOC) chemotherapy. The effect of blinatumomab on overall survival and reduction of minimal residual disease compared to SOC chemotherapy will also be investigated.
Patients will be randomized in a 1:1 ratio to receive either one cycle of blinatumomab or one block of standard high-risk consolidation chemotherapy. Blinatumomab is administered as a continuous intravenous infusion (CIVI). One cycle of blinatumomab treatment includes 4 weeks of CIVI of blinatumomab. After completing consolidation therapy, the patients should undergo alloHSCT depending on their bone marrow status. The patients will be followed up until the last subject on study is 36 months following alloHSCT or has died, whichever is first.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One week of treatment with HC3 followed by 3 weeks of no treatment. The standard intensive consolidation chemotherapy course HC3 includes dexamethasone (10 mg/m\^2/day intravenous \[IV\] on Days 1-6), vincrisitne (1.5 mg/m\^2/day IV on Days 1 and 6), daunorubicin (30 mg/m\^2 IV over 24 hours on Day 5), methotrexate (1 g/m\^2 IV over 36 hours on Day 1), ifosfamide (800 mg/m\^2 IV for 1 hour on Days 2-4), and pegylated \[PEG\]-asparaginase (1000 U/m\^2 IV for 2 hours or intramuscularly \[IM\] on Day 6) or, if allergic, erwinia-asparaginase (20,000 units/m\^2 IV or IM every 48 hours for a total of 6 doses).
Drug: Dexamethasone · Drug: Vincrisitne · Drug: Daunorubicin · Drug: Methotrexate · Drug: Ifosfamide · Drug: PEG-asparaginase · Drug: Erwinia-asparaginase
15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
Drug: Blinatumomab
15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
Also known as: Blincyto, AMG103
10 mg/m\^2/day intravenous (IV) on Days 1-6
1.5 mg/m\^2/day IV on Days 1 and 6
30 mg/m\^2 IV over 24 hours on Day 5
1 g/m\^2 IV over 36 hours on Day 1
800 mg/m\^2 IV for 1 hour on Days 2-4
1000 U/m\^2 IV for 2 hours or intramuscularly (IM) on Day 6
In case of allergic reaction to PEG-asparaginase, participants could change to erwinia-asparaginase, 20,000 units/m2 every 48 hours for a total of 6 doses
Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis)
EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with ≥ 5% and \< 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.
Time frame: As of the primary analysis data cutoff date (17 July 2019), overall median follow-up time for EFS was 22.4 months.
Kaplan Meier Estimate: EFS (Final Analysis)
EFS is calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with IP or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.
Time frame: At final analysis, overall median follow-up time for EFS was 51.9 months.
Kaplan Meier Estimate: Overall Survival (OS)
OS was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive. Months were calculated as days from randomization date to event/censor date, divided by 30.5.
Time frame: At final analysis, overall median follow-up time for OS was 55.2 months.
Percentage of Participants With an MRD Response Within 29 Days of Treatment Initiation
At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. MRD response was defined as MRD level \< 10\^-4, by polymerase chain reaction (PCR) or flow cytometry, at the end of treatment (Cycle 1 Day 29) with study drug. Participants who were part of the MRD Evaluable Set and were missing the end of treatment (Cycle 1 Day 29) assessment for a respective MRD assessment method were considered not to have achieved a response.
Time frame: Up to End of Treatment (Cycle 1, Day 29)
Cumulative Incidence of Relapse (CIR)
CIR estimate, presented as median months to relapse, calculated from date of achievement of first CR, using the cumulative incidence method (Fine JP, Gray RJ:1999). Deaths prior to relapse not considered related to an otherwise undocumented relapse were treated as a competing risk. Participants still alive without a date of relapse were censored at the time of last follow-up. Relapse=presence of ≥1 of the following: * isolated bone marrow relapse (M3 marrow \[representative bone marrow aspirate or biopsy with ≥25% blasts\] in the absence of extramedullary involvement) * combined bone marrow relapse (M2 \[representative bone marrow aspirate or biopsy with ≥5% and \<25% blasts\] or M3 marrow and ≥1 extramedullary manifestation of acute lymphoblastic leukemia) * central nervous system extramedullary relapse * testicular extramedullary relapse * extramedullary relapse at other sites Months were calculated as days from randomization to event/censor date, divided by 30.5.
Time frame: At final analysis, the overall maximum follow-up time was 82.0 months.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events (TRAEs)
Adverse event (AE): any untoward medical occurrence. Serious AE: an AE meeting at least 1 of the following serious criteria: fatal; life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Severity was graded according to the Common Terminology Criteria for AEs (CTCAE) version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Investigational product (IP) in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine, and in the blinatumomab arm refers to blinatumomab. Treatment-related refers to the assessment of a relationship between IP and the event.
Time frame: From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Number of Participants With TEAEs of Interest
TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.
Time frame: From first dose of IP through the last dose of IP (up to Day 29) plus 30 days.
Number of Participants With Shifts From Baseline Grade 0 or 1 to Worst Postbaseline Grade 3 or 4 Clinical Chemistry and Hematology Values
Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Increases (↑) or decreases (↓) in laboratory value grades (Gr) from baseline (BL) to worst postbaseline (→ PB) grade are presented. NA=not available.
Time frame: Up to Day 29 (± 2 days).
Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT)
The analysis of 100-day mortality after alloHSCT was assessed for participants who received an alloHSCT while in remission and did not receive any additional anti-leukemic treatment. 100-day mortality after alloHSCT was calculated relative to the date of alloHSCT. The 100-day mortality rate after alloHSCT was defined as the percentage of participants having died up to 100 days after alloHSCT, estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive were censored at the date they were last known to be alive.
Time frame: From the date of alloHSCT until death/censor date; median follow up time was 1742.0 days for blinatumomab and 1619.0 days for HC3.
Number of Participants With Anti-Blinatumomab Antibodies Postbaseline (Blinatumomab Arm Only)
Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.
Time frame: Day 1 to Day 29.
Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only)
Time frame: Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only)
Time frame: Day 1: at least 10 hours after infusion start and up to 24 hours; Day 15
This study was conducted at 48 centers across 13 countries (Europe, Australia, Israel). The first participant was enrolled on 10 November 2015. The last participant enrolled on 30 August 2019. The primary completion date was 17 July 2019 and the study completion date was 21 November 2022.
| Milestone | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Started | 57 | 54 |
| Participants treated | 52 | 54 |
| Participants in the primary analysis population | 54 | 54 |
| Participants in the final analysis population | 57 | 54 |
| Completed | 16 | 33 |
| Not completed | 41 | 21 |
| Withdrew: Decision by sponsor | 2 | 4 |
| Withdrew: Withdrawal by subject | 11 | 6 |
| Withdrew: Death | 27 | 10 |
| Withdrew: Lost to follow-up | 1 | 1 |
EFS is calculated from the time of randomization until the date of relapse or M2 marrow (representative bone marrow aspirate or biopsy with ≥ 5% and \< 25% blasts) after having achieved a complete remission (CR), failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with investigational product (IP) or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.
| months | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) | 7.4 (4.5 to 12.7) | NA (12.0 to NA) |
EFS is calculated from the time of randomization until the date of relapse or M2 marrow after having achieved a CR, failure to achieve a CR at the end of treatment, second malignancy, or death due to any cause, whichever occurs first. Participants who failed to achieve a CR following treatment with IP or who died before the disease assessment at the end of treatment were considered treatment failures and assigned an EFS duration of 1 day. Participants still alive and event-free were censored on their last disease assessment date. Participants were said to be in CR when they had the following: * M1 marrow * Peripheral blood without blasts * Absence of extramedullary leukemic involvement Months are calculated as days from randomization date to event/censor date, divided by 30.5.
| months | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Kaplan Meier Estimate: EFS (Final Analysis) | 7.8 (5.8 to 13.4) | NA (24.8 to NA) |
OS was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive. Months were calculated as days from randomization date to event/censor date, divided by 30.5.
| months | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Kaplan Meier Estimate: Overall Survival (OS) | 25.6 (17.5 to NA) | NA (NA to NA) |
At the end of the first treatment cycle (Day 29) a bone marrow aspiration/biopsy was performed and evaluated by the central MRD laboratory. MRD response was defined as MRD level \< 10\^-4, by polymerase chain reaction (PCR) or flow cytometry, at the end of treatment (Cycle 1 Day 29) with study drug. Participants who were part of the MRD Evaluable Set and were missing the end of treatment (Cycle 1 Day 29) assessment for a respective MRD assessment method were considered not to have achieved a response.
| percentage of participants | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| MRD Response by PCR | 53.1 (38.3 to 67.5) | 93.9 (83.1 to 98.7) |
| MRD Response by Flow Cytometry | 60.0 (45.9 to 73.0) | 92.6 (82.1 to 97.9) |
CIR estimate, presented as median months to relapse, calculated from date of achievement of first CR, using the cumulative incidence method (Fine JP, Gray RJ:1999). Deaths prior to relapse not considered related to an otherwise undocumented relapse were treated as a competing risk. Participants still alive without a date of relapse were censored at the time of last follow-up. Relapse=presence of ≥1 of the following: * isolated bone marrow relapse (M3 marrow \[representative bone marrow aspirate or biopsy with ≥25% blasts\] in the absence of extramedullary involvement) * combined bone marrow relapse (M2 \[representative bone marrow aspirate or biopsy with ≥5% and \<25% blasts\] or M3 marrow and ≥1 extramedullary manifestation of acute lymphoblastic leukemia) * central nervous system extramedullary relapse * testicular extramedullary relapse * extramedullary relapse at other sites Months were calculated as days from randomization to event/censor date, divided by 30.5.
| months | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Cumulative Incidence of Relapse (CIR) | 7.9 (5.8 to 18.6) | NA (NA to NA) |
Adverse event (AE): any untoward medical occurrence. Serious AE: an AE meeting at least 1 of the following serious criteria: fatal; life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; congenital anomaly/birth defect; other medically important serious event. Severity was graded according to the Common Terminology Criteria for AEs (CTCAE) version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Investigational product (IP) in the HC3 arm refers to dexamethasone, methotrexate, daunorubicin, erwinase, ifosfamide, asparaginase, and vincristine, and in the blinatumomab arm refers to blinatumomab. Treatment-related refers to the assessment of a relationship between IP and the event.
| participants | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| TEAEs | 50 | 54 |
| TEAEs Grade ≥ 3 | 43 | 33 |
| Serious TEAEs | 24 | 15 |
| Fatal TEAEs | 0 | 0 |
| TEAEs Leading to Discontinuation of IP | 0 | 2 |
| TEAEs Leading to Interruption of IP | 2 | 6 |
| TRAEs | 41 | 45 |
| TRAEs Grade ≥ 3 | 33 | 9 |
| Serious TRAEs | 15 | 9 |
| Fatal TRAEs | 0 | 0 |
| TRAEs Leading to Discontinuation of IP | 0 | 2 |
| TRAEs Leading to Interruption of IP | 2 | 5 |
TEAEs of interest included capillary leak syndrome (CLS), cytokine release syndrome (CRS), decreased immunoglobulins (DI), elevated liver enzymes (ELE), embolic and thrombotic events (ETE), infections (INF), infusion reactions without considering duration (IRWCD), medication errors (ME), neurologic events (NE), neutropenia and febrile neutropenia (NFN), pancreatitis (PNC), tumor lysis syndrome, leukoencephalopathy, immunogenicity. Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death.
| participants | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| CLS Events | 1 | 0 |
| CLS Events Grade ≥ 3 | 1 | 0 |
| Serious CLS Events | 1 | 0 |
| Fatal CLS Events | 0 | 0 |
| CLS Events Leading to Discontinuation of IP | 0 | 0 |
| CLS Events Leading to Interruption of IP | 0 | 0 |
| CRS Events | 1 | 2 |
| CRS Events Grade ≥ 3 | 0 | 0 |
| Serious CRS Events | 0 | 0 |
| Fatal CRS Events | 0 | 0 |
| CRS Events Leading to Discontinuation of IP | 0 | 0 |
| CRS Events Leading to Interruption of IP | 0 | 0 |
| DI Events | 6 | 9 |
| DI Events Grade ≥ 3 | 1 | 1 |
| Serious DI Events | 0 | 1 |
| Fatal DI Events | 0 | 0 |
| DI Events Leading to Discontinuation of IP | 0 | 0 |
| DI Events Leading to Interruption of IP | 0 | 0 |
| ELE Events | 15 | 7 |
| ELE Events Grade ≥ 3 | 9 | 3 |
| Serious ELE Events | 1 | 0 |
| Fatal ELE Events | 0 | 0 |
| ELE Events Leading to Discontinuation of IP | 0 | 0 |
| ELE Events Leading to Interruption of IP | 0 | 0 |
| ETE Events | 0 | 4 |
| ETE Events Grade ≥ 3 | 0 | 2 |
| Serious ETE Events | 0 | 0 |
| Fatal ETE Events | 0 | 0 |
| ETE Events Leading to Discontinuation of IP | 0 | 0 |
| ETE Events Leading to Interruption of IP | 0 | 0 |
| INF Events | 18 | 25 |
| INF Events Grade ≥ 3 | 6 | 11 |
| Serious INF Events | 6 | 4 |
| Fatal INF Events | 0 | 0 |
| IFN Events Leading to Discontinuation of IP | 0 | 0 |
| IFN Events Leading to Interruption of IP | 0 | 0 |
| IRWCD Events | 4 | 37 |
| IRWCD Events Grade ≥ 3 | 0 | 2 |
| Serious IRWCD Events | 0 | 1 |
| Fatal IRWCD Events | 0 | 0 |
| IRWCD Events Leading to Discontinuation of IP | 0 | 0 |
| IRWCD Events Leading to Interruption of IP | 0 | 0 |
| ME Events | 0 | 1 |
| ME Events Grade ≥ 3 | 0 | 0 |
| Serious ME Events | 0 | 1 |
| Fatal ME Events | 0 | 0 |
| ME Events Leading to Discontinuation of IP | 0 | 0 |
| ME Events Leading to Interruption of IP | 0 | 1 |
| NE Events | 15 | 26 |
| NE Events Grade ≥ 3 | 1 | 3 |
| Serious NE Events | 1 | 5 |
| Fatal NE Events | 0 | 0 |
| NE Events Leading to Discontinuation of IP | 0 | 2 |
| NE Events Leading to Interruption of IP | 1 | 3 |
| NFN Events | 28 | 12 |
| NFN Events Grade ≥ 3 | 27 | 11 |
| Serious NFN Events | 12 | 0 |
| Fatal NFN Events | 0 | 0 |
| NFN Events Leading to Discontinuation of IP | 0 | 0 |
| NFN Events Leading to Interruption of IP | 0 | 0 |
| PNC Events | 1 | 0 |
| PNC Events Grade ≥ 3 | 1 | 0 |
| Serious PNC Events | 1 | 0 |
| Fatal PNC Events | 0 | 0 |
| PNC Events Leading to Discontinuation of IP | 0 | 0 |
| PNC Events Leading to Interruption of IP | 0 | 0 |
| Tumour Lysis Syndrome Events | 0 | 0 |
| Leukoencephalopathy Events | 0 | 0 |
| Immunogenicity Events | 0 | 0 |
Severity was graded according to the CTCAE version 4.03: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Increases (↑) or decreases (↓) in laboratory value grades (Gr) from baseline (BL) to worst postbaseline (→ PB) grade are presented. NA=not available.
| participants | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Potassium ↑ BL Gr 0 → PB Gr 3 | 0 | 1 |
| Potassium ↓ BL Gr 0 → PB Gr 3 | 4 | 5 |
| Potassium ↓ BL Gr 0 → PB Gr 4 | 1 | 1 |
| Albumin ↓ BL Gr 0 → PB Gr 3 | 0 | 1 |
| Calcium ↓ BL Gr 0 → PB Gr 4 | 1 | 1 |
| Alanine Aminotransferase ↑ BL Gr 0 → PB Gr 3 | 1 | 0 |
| Alanine Aminotransferase ↑ BL Gr 1 → PB Gr 3 | 9 | 5 |
| Aspartate Aminotransferase ↑ BL Gr NA → PB Gr 3 | 1 | 0 |
| Aspartate Aminotransferase ↑ BL Gr 0 → PB Gr 3 | 2 | 0 |
| Aspartate Aminotransferase ↑ BL Gr 1 → PB Gr 3 | 5 | 1 |
| Aspartate Aminotransferase ↑ BL Gr 1 → PB Gr 4 | 1 | 0 |
| Gamma-Glutamyl Transferase ↑ BL Gr NA → PB Gr 3 | 0 | 1 |
| Gamma-Glutamyl Transferase ↑ BL Gr 0 → PB Gr 3 | 3 | 4 |
| Gamma-Glutamyl Transferase ↑ BL Gr 1 → PB Gr 3 | 6 | 2 |
| Gamma-Glutamyl Transferase ↑ BL Gr 1 → PB Gr 4 | 0 | 3 |
| Amylase ↑ BL Gr 0 → PB Gr 3 | 1 | 1 |
| Amylase ↑ BL Gr 0 → PB Gr 4 | 1 | 0 |
| Amylase ↑ BL Gr 1 → PB Gr 3 | 0 | 1 |
| Lipase ↑ BL Gr 0 → PB Gr 3 | 3 | 2 |
| Lipase ↑ BL Gr 0 → PB Gr 4 | 1 | 2 |
| Bilirubin ↑ BL Gr 0 → PB Gr 3 | 2 | 1 |
| Bilirubin ↑ BL Gr 0 → PB Gr 4 | 1 | 0 |
| Creatinine ↑ BL Gr NA → PB Gr 3 | 0 | 2 |
| Hemoglobin ↓ BL Gr 0 → PB Gr 3 | 1 | 0 |
| Hemoglobin ↓ BL Gr 1 → PB Gr 3 | 4 | 1 |
| Platelets ↓ BL Gr 0 → PB Gr 3 | 7 | 6 |
| Platelets ↓ BL Gr 0 → PB Gr 4 | 13 | 6 |
| Platelets ↓ BL Gr 1 → PB Gr 3 | 1 | 2 |
| Platelets ↓ BL Gr 1 → PB Gr 4 | 8 | 2 |
| Leukocytes ↓ BL Gr 0 → PB Gr 3 | 2 | 0 |
| Leukocytes ↓ BL Gr 0 → PB Gr 4 | 4 | 0 |
| Leukocytes ↓ BL Gr 1 → PB Gr 3 | 4 | 4 |
| Leukocytes ↓ BL Gr 1 → PB Gr 4 | 7 | 1 |
| Neutrophils ↓ BL Gr 0 → PB Gr 3 | 4 | 11 |
| Neutrophils ↓ BL Gr 0 → PB Gr 4 | 23 | 3 |
| Lymphocytes ↑ BL Gr 0 → PB Gr 3 | 0 | 1 |
| Lymphocytes ↓ BL Gr 0 → PB Gr 3 | 1 | 3 |
| Lymphocytes ↓ BL Gr 0 → PB Gr 4 | 1 | 1 |
| Lymphocytes ↓ BL Gr 1 → PB Gr 3 | 0 | 1 |
| Lymphocytes ↓ BL Gr 1 → PB Gr 4 | 1 | 2 |
The analysis of 100-day mortality after alloHSCT was assessed for participants who received an alloHSCT while in remission and did not receive any additional anti-leukemic treatment. 100-day mortality after alloHSCT was calculated relative to the date of alloHSCT. The 100-day mortality rate after alloHSCT was defined as the percentage of participants having died up to 100 days after alloHSCT, estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants still alive were censored at the date they were last known to be alive.
| percentage of participants | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Kaplan-Meier Estimate of 100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) | 5.1 (1.3 to 19.0) | 3.9 (1.0 to 14.8) |
Participants receiving blinatumomab had blood samples analyzed for binding antibodies. Samples testing positive for binding antibodies were also tested for neutralizing antibodies. Participants who were binding antibody-positive or neutralizing antibody-positive post-baseline with a negative or no result at baseline are presented.
| participants | Blinatumomab |
|---|---|
| Binding Antibody Positive | 0 |
| Neutralizing Antibody Positive | 0 |
| pg/mL | Blinatumomab |
|---|---|
| Pharmacokinetics: Concentration at Steady State (Css) (Blinatumomab Arm Only) | 884 ± 969 |
| L/hr/m^2 | Blinatumomab |
|---|---|
| Pharmacokinetics: Clearance (CL) (Blinatumomab Arm Only) | 1.14 ± 0.836 |
Collected over All-cause mortality is reported from randomization through the end of study; the median overall follow-up time was 55.2 months. Treatment-emergent adverse events are reported from the first dose of IP through the last dose of IP (up to Day 29) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HC3 Chemotherapy | 28/57 (49.1%) | 24/52 (46.2%) | 48/52 (92.3%) |
| Blinatumomab | 11/54 (20.4%) | 15/54 (27.8%) | 54/54 (100%) |
| Event | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 9/52 | 0/54 |
| NeutropeniaBlood and lymphatic system disorders | 3/52 | 0/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/52 | 0/54 |
| StomatitisGastrointestinal disorders | 2/52 | 1/54 |
| Neurological symptomNervous system disorders | 0/52 | 2/54 |
| SeizureNervous system disorders | 0/52 | 2/54 |
| LeukopeniaBlood and lymphatic system disorders | 1/52 | 0/54 |
| Pancreatitis acuteGastrointestinal disorders | 1/52 | 0/54 |
| HepatotoxicityHepatobiliary disorders | 1/52 | 0/54 |
| HypertransaminasaemiaHepatobiliary disorders | 1/52 | 0/54 |
| Event | HC3 Chemotherapy | Blinatumomab |
|---|---|---|
| PyrexiaGeneral disorders | 10/52 | 43/54 |
| StomatitisGastrointestinal disorders | 27/52 | 11/54 |
| AnaemiaBlood and lymphatic system disorders | 24/52 | 13/54 |
| NauseaGastrointestinal disorders | 9/52 | 23/54 |
| HeadacheNervous system disorders | 8/52 | 20/54 |
| VomitingGastrointestinal disorders | 11/52 | 17/54 |
| NeutropeniaBlood and lymphatic system disorders | 13/52 | 5/54 |
| DiarrhoeaGastrointestinal disorders | 9/52 | 12/54 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/52 | 4/54 |
| Abdominal painGastrointestinal disorders | 11/52 | 7/54 |
The FAS included all randomized participants analyzed according to their randomized treatment assignment, regardless of the treatment received.
| Age, Continuous(years) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| Mean | 6.6 ± 4.3 | 7.3 ± 4.4 | 7.0 ± 4.4 |
| Sex: Female, Male(Participants) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| Female | 34 | 24 | 58 |
| Male | 23 | 30 | 53 |
| Ethnicity (NIH/OMB)(Participants) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 1 | 4 |
| Not Hispanic or Latino | 54 | 53 | 107 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| White | 46 | 50 | 96 |
| Other, Not Specified | 5 | 3 | 8 |
| Asian | 3 | 1 | 4 |
| Black or African American | 3 | 0 | 3 |
| Stratification Factor: Age Category(Participants) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| 1 to 9 years | 41 | 39 | 80 |
| Other (< 1 year and > 9 years) | 16 | 15 | 31 |
| Stratification Factor: Marrow/Minimal Residual Disease (MRD)(participants) | HC3 Chemotherapy | Blinatumomab | Total |
|---|---|---|---|
| M1 Marrow + MRD level ≥ 10^-3 | 17 | 15 | 32 |
| M1 Marrow + MRD level < 10^-3 | 36 | 35 | 71 |
| M2 Marrow | 4 | 4 | 8 |
Showing the first 100 of 103 sites across 24 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from Nov 2015 to primary completion in Jul 2019, 44 months.
Results were first posted in Jul 2020, 11 months after primary completion.
Of 59 phase 3 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 86 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 104. This study's 44 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
Precursor Cell Lymphoblastic Leukemia-Lymphoma →